BRAF mutations in metastatic melanoma: A possible association with clinical outcome

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3362-3368

  Kumar, Rajiv ^a,b   Angelini, Sabrina ^a   Czene, Kamila ^a   Sauroja, Ilari ^c   Hahka Kemppinen, Marjo ^d   Pyrhönen, Seppo ^c   Hemminki, Kari ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF TURKU   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; CELL GROWTH; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; MELANOCYTE; MELANOMA; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; BASE SEQUENCE; EXONS; FEMALE; GENES, RAS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; TIME FACTORS; TREATMENT OUTCOME;

EID: 0041333110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chin, L., Merlino, G., and DePinho, R. A. Malignant melanoma: modern black plague and genetic black box. Genes Dev., 12: 3467-3481, 1998.
2. Gilchrest, B. A., Eller, M. S., Geller, A. C., and Yaar, M. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med., 340: 1341-1348, 1999.
3. Hemminki, K., Lonnstedt, I., and Vaittinen, P. A population-based study of familial cutaneous melanoma. Melanoma Res., 11: 133-140, 2001.
4. ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer, 23: 273-277, 1998.
5. Bishop, D. T., Demenais, F., Goldstein, A. M., Bergman, W., Bishop, J. N., Bressac-de Paillerets, B., Chompret, A., Ghiorzo, P., Gruis, N., Hansson, J., Harland, M., Hayward, N., Holland, E. A., Mann, G. J., Mantelli, M., Nancarrow, D., Platz, A., and Tucker, M. A. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl. Cancer Inst. (Bethesda), 94: 894-903, 2002.
6. Kumar, R., Smeds, J., Lundh Rozell, B., and Hemminki, K. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res., 9: 138-147, 1999.
7. Saida, T. Recent advances in melanoma research. J. Dermatol. Sci., 26: 1-13, 2001.
8. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
9. Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux, C., Eychene, A., Ortonne, J. P., and Ballotti, R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J., 19: 2900-2910, 2000.
10. Sauroja, I., Smeds, J., Vlaykova, T., Kumar, R., Talve, L., Hahka-Kemppinen, M., Punnonen, K., Jansen, C. T., Hemminki, K., and Pyrhonen, S. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer, 28: 404-414, 2000.
11. Ketcham, A. S., Moffat, F. L., and Balch, C. M. Classification and staging. In: C. M. Balch, A. N. Houghton, G. W. Milton, A. J. Sober, and S-J. Soong (eds.), Cutaneous Melanoma, pp. 213-220. Philadelphia: J. B. Lippincott Co., 1992.
12. Pyrhonen, S., Hahka-Kemppinen, M., and Muhonen, T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J. Clin. Oncol., 10: 1919-1926, 1992.
13. Hahka-Kemppinen, M., Muhonen, T., Virolainen, M., Jekunen, A., Asko-Seljavaara, S., and Pyrhonen, S. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br. J. Dermatol., 132: 973-977, 1995.
14. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
15. Sithanandam, G., Kolch, W., Duh, F. M., and Rapp, U. R. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene, 5: 1775-1780, 1990.
16. Sithanandam, G., Druck, T., Cannizzaro, L. A., Leuzzi, G., Huebner, K., and Rapp, U. R. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene, 7: 795-799, 1992.
17. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond.), 418: 934, 2002.
18. Pollock, P. M., and Meltzer, P. S. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell, 2: 5-7, 2002.
19. Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., and Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res., 62: 7001-7003, 2002.
20. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J. A., Albelda, S. M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P. A., Wooster, R., Stratton, M. R., and Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 62: 6997-7000, 2002.
21. Yuen, S. T., Davies, H., Chan, T. L., Ho, J. W., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S., Futreal, P. A., Stratton, M. R., Wooster, R., and Leung, S. Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res., 62: 6451-6455, 2002.
22. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
23. Singer, G., Oldt, R., III, Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., and Shih Ie, M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. (Bethesda), 95: 484-486, 2003.
24. Lang, J., Boxer, M., and MacKie, R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat., 21: 327-330, 2003.
25. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res., 63: 1454-1457, 2003.
26. Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., and Sidransky, D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. (Bethesda), 95: 625-627, 2003.
27. Smalley, K. S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer, 104: 527-532, 2003.
28. Satyamoorthy, K., Li, G., Gerrero. M. R., Brose, M. S., Volpe, P., Weber, B. L., Van Belle, P., Elder, D. E., and Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res., 63: 756-759, 2003.
29. Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U., and Hansson, J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin. Cancer Res., 8: 3468-3474, 2002.